Acurx reports Q4 net loss $5.1M; ibezapolstat Phase 2b shows 96% cure rate

Acurx Pharmaceuticals, Inc.

Q4 net loss $5.1M ($0.37/shr); full year net loss $14.6M ($1.15/shr).
Year-end cash $7.5M; subsequent ATM raised ~$4.5M.
Ibezapolstat Phase 2b: 96% clinical cure (25/26), 100% sustained cure at 30 days.
FDA End of Phase 2 meeting scheduled April 2024; Phase 3 plan to be discussed.
EMA granted SME designation; additional microbiome data positive vs vancomycin.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Acurx Pharmaceuticals, Inc. reported the three months ended December 31, 2023 results: net income $5.1 million, EPS $0.37 per diluted share.

Period: the three months ended December 31, 2023
Net income: $5.1 million
EPS: $0.37 per diluted share
Result: reported results

Exact text from the filing

The Company reported a net loss of $5.1 million or $0.37 per diluted share for the three months ended December 31, 2023 compared to a net loss of $3.3 million or $0.28 per diluted share for the three months ended December 31, 2022

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Acurx Pharmaceuticals, Inc. reported the year ended December 31, 2023 results: net income $14.6.

Period: the year ended December 31, 2023
Net income: $14.6
Result: reported results

Exact text from the filing

oss of $3.3 million or $0.28 per diluted share for the three months ended December 31, 2022, and a net loss of $14.6

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Acurx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-035556

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.